NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.85 +0.21 (+2.18 %) (As of 02/22/2019 04:00 PM ET)Previous Close$9.85Today's Range$9.67 - $9.9552-Week Range$9.21 - $27.98Volume329,595 shsAverage Volume184,381 shsMarket Capitalization$205.80 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois. Receive XERS News and Ratings via Email Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XERS Previous Symbol CUSIPN/A CIKN/A Webwww.xerispharma.com Phone844-445-5704Debt Debt-to-Equity Ratio0.33 Current Ratio16.55 Quick Ratio16.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.55 million Price / Sales132.77 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees55 Outstanding Shares20,893,000Market Cap$205.80 million Next Earnings Date2/27/2019 (Estimated) OptionableNot Optionable Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions What is Xeris Pharmaceuticals' stock symbol? Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS." How were Xeris Pharmaceuticals' earnings last quarter? Xeris Pharmaceuticals Inc (NASDAQ:XERS) issued its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.07. The company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $0.30 million. View Xeris Pharmaceuticals' Earnings History. When is Xeris Pharmaceuticals' next earnings date? Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Xeris Pharmaceuticals. What price target have analysts set for XERS? 4 Wall Street analysts have issued 12 month price objectives for Xeris Pharmaceuticals' stock. Their forecasts range from $23.00 to $27.00. On average, they expect Xeris Pharmaceuticals' stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 148.7% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals. What is the consensus analysts' recommendation for Xeris Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals. What are Wall Street analysts saying about Xeris Pharmaceuticals stock? Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock: 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019) 2. Mizuho analysts commented, "We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share." (12/4/2018) Has Xeris Pharmaceuticals been receiving favorable news coverage? News articles about XERS stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Xeris Pharmaceuticals' key competitors? Some companies that are related to Xeris Pharmaceuticals include CytomX Therapeutics (CTMX), Apellis Pharmaceuticals (APLS), Y-mAbs Therapeutics (YMAB), Inflarx (IFRX), G1 Therapeutics (GTHX), Vectura Group (VEGPF), Intra-Cellular Therapies (ITCI), ANI Pharmaceuticals (ANIP), Arvinas (ARVN), Principia Biopharma (PRNB), Evolus (EOLS), Omeros (OMER), Eagle Pharmaceuticals (EGRX), CymaBay Therapeutics (CBAY) and Dicerna Pharmaceuticals (DRNA). What other stocks do shareholders of Xeris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include AbbVie (ABBV), Cytori Therapeutics (CYTX), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH), Spark Therapeutics (ONCE), Tesla (TSLA), Madrigal Pharmaceuticals (MDGL), Innovative Industrial Properties (IIPR), Pfizer (PFE) and Colgate-Palmolive (CL). Who are Xeris Pharmaceuticals' key executives? Xeris Pharmaceuticals' management team includes the folowing people: Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)Mr. John P. Shannon, Exec. VP & COO (Age 57)Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications When did Xeris Pharmaceuticals IPO? (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Pharmaceuticals' major shareholders? Xeris Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.09%), Geode Capital Management LLC (0.40%), Northern Trust Corp (0.36%), Bank of New York Mellon Corp (0.10%) and New York State Common Retirement Fund (0.02%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals. Which institutional investors are buying Xeris Pharmaceuticals stock? XERS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Bank of New York Mellon Corp, New York State Common Retirement Fund and Northern Trust Corp. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, Palmetto Partners, Ltd and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals. How do I buy shares of Xeris Pharmaceuticals? Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Xeris Pharmaceuticals' stock price today? One share of XERS stock can currently be purchased for approximately $9.85. How big of a company is Xeris Pharmaceuticals? Xeris Pharmaceuticals has a market capitalization of $205.80 million and generates $1.55 million in revenue each year. Xeris Pharmaceuticals employs 55 workers across the globe. What is Xeris Pharmaceuticals' official website? The official website for Xeris Pharmaceuticals is http://www.xerispharma.com. How can I contact Xeris Pharmaceuticals? Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected] MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 31 (Vote Outperform)Underperform Votes: 43 (Vote Underperform)Total Votes: 74MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: How Do You Calculate Return on Equity (ROE)?